Kura Oncology (NASDAQ:KURA) SVP Sells $60,421.32 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 7,142 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $60,421.32. Following the completion of the transaction, the senior vice president owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. This represents a 4.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas James Doyle also recently made the following trade(s):

• On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total transaction of $50,746.02.

Kura Oncology Trading Up 2.2%

NASDAQ KURA opened at $8.22 on Friday. The stock has a market cap of $715.30 million, a P/E ratio of -3.31 and a beta of 0.25. The company’s fifty day simple moving average is $10.21 and its 200-day simple moving average is $9.04. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $12.49.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million. Equities research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after buying an additional 3,769 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares during the period. Brevan Howard Capital Management LP bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $80,000. Finally, Merit Financial Group LLC acquired a new stake in Kura Oncology during the third quarter worth about $89,000.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KURA. Barclays restated an “overweight” rating and set a $28.00 price objective (up previously from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. UBS Group increased their target price on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, November 14th. JMP Securities restated a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.